Trial Profile
Study comparing effectiveness between tofacitinib and bDMARDs in rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2020
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary) ; Abatacept; Abatacept; Adalimumab; Adalimumab; Certolizumab pegol; Certolizumab pegol; Disease-modifying antirheumatics; Disease-modifying antirheumatics; Etanercept; Etanercept; Golimumab; Golimumab; Infliximab; Infliximab; Tocilizumab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 01 Oct 2020 Results (n=18834) published in The Journal of Rheumatology
- 21 Sep 2018 New trial record
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management